Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;59(4):641-653.
doi: 10.1007/s10597-022-01045-2. Epub 2022 Nov 10.

Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic

Catherine W Bennett  1   2   3   4 , Lauren Gensler  5   6   7 , David R Goldsmith  5   7
Affiliations

Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic

Catherine W Bennett et al. Community Ment Health J. 2023 May.

Abstract

Patients with psychotic disorders have increased rates of medical comorbidities. In this cross-sectional study, we investigated the relationship between antipsychotics and medical comorbidities among patients with psychotic disorders in an urban psychiatry clinic in Atlanta, Georgia (n = 860). Each antipsychotic group was compared to a group of patients from the same sample who were not on any antipsychotic, and logistic regression models were constructed for each comorbidity. Ziprasidone was associated with diabetes (aOR 2.56, 95% CI 1.03-6.38) and obesity (aOR 3.19, 95% CI 1.37-7.41). Aripiprazole was associated with obesity (aOR 2.39, 95% CI 1.27-4.51). Clozapine was associated with GERD (aOR 3.59, 95% CI 1.11-11.61), movement disorders (aOR 4.44, 95% CI 1.02-19.32), and arrythmias (4.89, 95% CI 1.44-16.64). Two antipsychotics that are considered weight neutral, ziprasidone and aripiprazole, were associated with cardiometabolic comorbidities. This study suggests that research is warranted to study the association between antipsychotics, medical comorbidity, and psychotic symptom burden.

Keywords: Cardiometabolic disorders; Clozapine; Medical comorbidity; Psychotic disorders; Substance use.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018). Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacology & Therapeutics, 192, 20–41. https://doi.org/10.1016/j.pharmthera.2018.06.012 - DOI
    1. Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weight-gain caused by antipsychotics: A systematic review and meta-analysis. Expert Opinion on Drug Safety, 19(3), 295–314. https://doi.org/10.1080/14740338.2020.1713091 - DOI - PubMed
    1. Bellon, A., & Nguyen, K. (2021). Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: A controversial but promising approach. World Journal of Psychiatry, 11(7), 316–324. https://doi.org/10.5498/wjp.v11.i7.316 - DOI - PubMed - PMC
    1. Bloechliger, M., Ruegg, S., Jick, S. S., Meier, C. R., & Bodmer, M. (2015). Antipsychotic drug use and the risk of seizures: Follow-up study with a nested case-control analysis. CNS Drugs, 29(7), 591–603. https://doi.org/10.1007/s40263-015-0262-y - DOI - PubMed
    1. Boden, R., Edman, G., Reutfors, J., Ostenson, C. G., & Osby, U. (2013). A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatric Disease and Treatment, 9, 371–377. https://doi.org/10.2147/NDT.S40554 - DOI - PubMed - PMC

Publication types

LinkOut - more resources